

initial intervention given its efficacy, safety, and patient acceptability. Other approaches, such as antipsychotic augmentation, have concerning side effect profiles<sup>12</sup> and have not consistently demonstrated superiority relative to placebo in methodologically rigorous controlled trials.<sup>10</sup>

We are grateful to Namouz-Haddad and Nulman<sup>1</sup> for providing an excellent review of OCD in pregnancy and puerperium and treatment options for this population. Disseminating accurate and reliable treatment information to clinicians is of critical importance, as safe and effective treatment for this population is necessary for the well-being of both the mothers and newborns. In an effort to present well-rounded treatment suggestions, we suggest a more thorough and balanced explanation of CBT and the inherent benefits of this empirically supported behavioural treatment.

—Brittney F. Dane  
—Eric A. Storch PhD  
Tampa, Fla

**Competing interests**

None declared

**References**

1. Namouz-Haddad S, Nulman I. Safety of treatment of obsessive compulsive disorder in pregnancy and puerperium. *Can Fam Physician* 2014;60:133-6.
2. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. *Am J Psychiatry* 2005;162(1):151-61.
3. Rosa-Alcázar AI, Sánchez-Meca J, Gómez-Conesa A, Marín-Martínez F. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. *Clin Psychol Rev* 2008;28(8):1310-25. Epub 2008 Jul 4.
4. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. *Am J Psychiatry* 2007;164(7 Suppl):5-53.
5. Christian LM, Storch EA. Cognitive behavioral treatment of postpartum onset. Obsessive compulsive disorder with aggressive obsessions. *Clin Case Stud* 2009;8(1):72-83.
6. Misri S, Reebye P, Corral M, Milis L. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. *J Clin Psychiatry* 2004;65(9):1236-41.
7. Patel SR, Simpson HB. Patient preferences for obsessive-compulsive disorder treatment. *J Clin Psychiatry* 2010;71(11):1434-9.
8. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. *Psychiatr Serv* 2003;54(8):1111-8.
9. Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR. Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. *J Anxiety Disord* 2003;17(4):461-78.
10. Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. *JAMA Psychiatry* 2013;70(11):1190-9. DOI: 10.1001/jamapsychiatry.2013.1932.
11. Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. *Am J Psychiatry* 2008;165(5):621-30. DOI: 10.1176/appi.ajp.2007.07091440. Epub 2008 Mar 3.
12. Gentile S. Infant safety with antipsychotic therapy in breast-feeding: a systematic review. *J Clin Psychiatry* 2008;69(4):666-73.

**Correction**

In the article "Imaging appropriateness criteria. Why Canadian family physicians should care," published in the March 2014 issue of *Canadian Family Physician*,<sup>1</sup> the correspondence information was incorrect. It should have read as follows:

**Dr Benjamin Fine**, Department of Medical Imaging, Faculty of Medicine, University of Toronto, 263 McCaul St, 4th Floor, Toronto, ON M5T 1W7; e-mail [ben.fine@utoronto.ca](mailto:ben.fine@utoronto.ca)

**Reference**

1. Fine B, Dhanoa D. Imaging appropriateness criteria. Why Canadian family physicians should care. *Can Fam Physician* 2014;60:217-8 (Eng), e144-6 (Fr).

**Correction**

Dans l'article intitulé en français «Critères de pertinence de l'imagerie. Pourquoi les médecins canadiens devraient s'en soucier» et, en anglais, «Imaging appropriateness criteria. Why Canadian family physicians should care», publié dans le numéro de mars 2014 du *Médecin de famille canadien*<sup>1</sup>, les coordonnées pour la correspondance étaient incorrectes et auraient dû se lire comme suit :

**Dr Benjamin Fine**, Department of Medical Imaging, Faculty of Medicine, University of Toronto, 263 McCaul St, 4th Floor, Toronto, ON M5T 1W7; courriel [ben.fine@utoronto.ca](mailto:ben.fine@utoronto.ca)

**Reference**

1. Fine B, Dhanoa D. Imaging appropriateness criteria. Why Canadian family physicians should care. *Can Fam Physician* 2014;60:217-8 (ang), e144-6 (Fr).